Department of Pathology, The George Washington University, Washington, DC.
Departments of Surgery.
Am J Dermatopathol. 2021 Aug 1;43(8):585-587. doi: 10.1097/DAD.0000000000001849.
Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.
基底细胞癌（BCC）是美国最常见的皮肤癌，每年有超过 250 万人接受治疗。遗传研究表明，大约 90%的 BCC 存在 hedgehog 信号通路的突变。BCC 患者通常具有良好的手术预后，然而，局部晚期 BCC 患者可能会因手术干预而导致明显的美容或功能障碍。Vismodegib 是一种 hedgehog 通路抑制剂，已成功用于治疗局部晚期 BCC 患者。我们报告了一例 BCC 患者，对 vismodegib 反应良好，切除标本中出现了新的黄色瘤样改变。
